James, A R; Unnikrishnan, B S; Priya, R; Joseph, M M; Manojkumar, T K; Raveendran Pillai, K; Shiji, R; Preethi, G U; Kusumakumary, P; Sreelekha, T T
(Sage Publications, 2017-03)
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side ...